Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The team proposed a prenatal depression detection method using the semantically enhanced option embedding (SEOE) model to ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

(HealthDay News) — Approximately four in 10 patients with osteoarthritis (OA) or rheumatoid arthritis (RA) have anxiety, depression, or fibromyalgia, according to a study published online July 16 in ...

Depression can be treated but the first step is determining whether symptoms are present. This test could help. Using the key below, answer the questions based on how strongly you agree or ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...